Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $2.1 to $1.4.
Star Equity Holdings’ KBS Builders Wins $1.9M Initial Contract For A Multi-Phase Affordable Housing Project In Maine
Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)))) ("Star Equity" or the "Company"), a diversified holding company, announced today that its KBS Builders, Inc. ("KBS") business has signed an approximately $1.9 million
